Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor tissue destruction by thermal injury is a therapeutic approach involving the application of extreme heat (hyperthermia) or cold (cryotherapy) to destroy cancerous tissue. Common technologies include radiofrequency ablation, microwave ablation, laser-induced thermotherapy, and high-intensity focused ultrasound. The mechanism is predominantly acute coagulative necrosis of tumor cells, with secondary effects including microvascular thrombosis, ischemia, and immune modulation. Destruction efficacy is challenged by the tumor microenvironment, heat dissipation due to nearby large blood vessels ("heat sink" effect), and the risk of collateral damage to surrounding healthy tissues. While highly effective for selected patients and tumors, this is a modality or process—not a molecular target or receptor—and is not a canonical drug target such as a receptor, enzyme, or transporter[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor tissue destruction by thermal injury.